Argen-X makes two appointments


Chief medical officer and IP counsel

Argen-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary Simple Antibody platform, has strengthened its management team by hiring Alain Thibault as chief medical officer, and Jacobus (Koos) Rasser as IP Counsel.

Prior to joining Argen-X, Thibault was therapeutic area head of oncology at Regeneron Pharmaceuticals where he was responsible for clinical development, product strategy and portfolio management, as well as coordination of the collaboration with Sanofi to develop fully human antibody products for multiple cancer indications. Prior to this, he held senior research positions at Johnson & Johnson and Hoffman La Roche.

Jacobus (Koos) Rasser

Jacobus (Koos) Rasser

Rasser was previously senior partner at the global IP law firm Howrey LLP and founded its London practice. Among his clients in the pharma/biotech field were Biogen Idec, Millennium Pharmaceuticals, Eppendorf, Schering Plough and Amersham. He also acted as interim IP Director at Akzo Nobel’s Organon Division.

Sign up for your free email newsletter

Prior to his tenure at Howrey, Rasser was head of the global IP organisation at Procter & Gamble.